Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03135834 · ClinicalTrials.gov registry record · Phase 3
A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,610
- Enrollment target
NCT03135834 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,610 participants.
The verdict
NCT03135834, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,610 participants
- Enrollment target
Study Summary
This study is examining safety and immunogenicity of 2 doses of Trumenba administered on a 0-,6- month schedule. This trial is also studying safety and immunogenicity of a meningococcal pentavalent vaccine.
Interventions
- BIOLOGICAL Saline
- BIOLOGICAL MenACWY-CRM
- BIOLOGICAL MenABCWY
- BIOLOGICAL rLP2086
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,610 participants |
| Start Date | 2017-04-24 |
| Est. Completion | 2022-10-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03135834
The ClinicalTrials.gov registry entry for NCT03135834 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,610 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Saline is the first listed.
NCT03135834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03135834 about?
NCT03135834 is a clinical study titled "A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.". This study is examining safety and immunogenicity of 2 doses of Trumenba administered on a 0-,6- month schedule. This trial is also studying safety and immunogenicity of a meningococcal pentavalent vaccine.
What is the current status of trial NCT03135834?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,610 participants. The study started on 2017-04-24. Estimated completion is 2022-10-25.
What interventions are being tested in trial NCT03135834?
The interventions under investigation include: Saline (BIOLOGICAL), MenACWY-CRM (BIOLOGICAL), MenABCWY (BIOLOGICAL), rLP2086 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03135834?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.